FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia

KENILWORTH, N.J., July 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets a...

Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients

SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

ROCHESTER, Minn., March 10 /PRNewswire-USNewswire/ -- Here are highlights from the March issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. Include the following subscri...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

MOUNTAIN VIEW, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its second Phase 3 clinical trial of AZ-004 (Staccato(R) loxapine). This Phase 3 clinical trial was conducted in patients with bipolar disorder experiencing...

NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression

Free, Public Event Provides Findings That Include Important Clues Toward the Development of Customized Treatment GREAT NECK, N.Y., May 30 /PRNewswire-USNewswire/ -- New findings from research supported by NARSAD, the world's leading charity dedicated to mental health research, and conducted ...

Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD)

GREEN BAY, Wis., May 15 /PRNewswire/ -- Omega 3 fatty acids bound to phospholipids deserves to be further considered as a credible natural alternative and may have beneficial effect on impulsivity in ADHD patients, recent in vivo French study reveals. While several studies have reported benefi...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

WILMINGTON, Del., May 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets to seek approval for the trea...

New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting

- Studies Evaluated Improvement in Symptoms Both in the Short and Long Term - WILMINGTON, Del., May 5 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced new study data on SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for the treat...

Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients

Initial Results Expected to be Reported in Q2 2008 MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) al...

Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders

ROCHESTER, Minn., April 15, 2008 /PRNewswire-USNewswire/ -- Three new Mayo Clinic studies find that REM (rapid eye movement) sleep behavior disorder is associated with anxiety, apathy, lower scores in attention and executive functioning, as well as symptoms of Parkinson's disease. The findings...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)

- Otsuka-sponsored Study Evaluated Use of ABILIFY In This Patient Population - TOKYO and PRINCETON, N.J., Feb. 29 /PRNewswire/ -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY ) announced today that the U.S. Food and Drug Administr...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of impro...

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

SAN FRANCISCO, May 19 /PRNewswire/ -- New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder. Results of the study were presented this wee...

Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder

Company to Submit a Supplemental New Drug Application to Expand the NUVIGIL(R) Label FRAZER, Pa., April 6 /PRNewswire-FirstCall/ -- Cephalon, Inc . (Nasdaq: CEPH ) today announced positive results from a phase three clinical trial of NUVIGIL(R) (armodafinil) Tablets [...

Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder

ROCHESTER, Minn., Feb. 11 /PRNewswire-USNewswire/ -- In a study published in The American Journal of Psychiatry , a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., attempted to identify what factors make some people with bipolar depression more likely to experience treatment-...

Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder

NEW YORK, Feb. 2 /PRNewswire-USNewswire/ -- A study led by Laurie Ozelius, Ph.D. at Mount Sinai School of Medicine has identified a gene associated with the development of primary torsion dystonia, also known as DYT6 dystonia. With funding provided by the Dystonia Medical Research Foundation (DMR...

U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder

Schering-Plough expects to respond to agency during first quarter KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS(TM) (asenapine) s...

Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- A study assessing the quality of care for patients with sickle cell disease in a variety of hospital settings will be presented at a press conference on Saturday, December 6, at 9:30 a.m., during the 50th Annual Meeting of the American Society of He...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

PHILADELPHIA, Nov. 20 /PRNewswire-FirstCall/ --GlaxoSmithKline (NYSE: GSK ) today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immu...

Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder

First Clinical Study of Paliperidone ER in this Under-Studied Condition SAN DIEGO, Nov. 1 /PRNewswire/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a significant improvement in their symptoms, according to a ne...

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder

NEW YORK and BUDAPEST, Hungary, Sept. 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Gedeon Richter Plc today announced preliminary top-line results from a phase II clinical trial of cariprazine (RGH-188), an investigational antipsychotic, in patients with acute mania...

Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder

Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

INDIANAPOLIS, June 27 /PRNewswire-FirstCall/ -- Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion supporting the approval of Cymbalta(R) (dul...

Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder

Reports Full Assessment of Data from Positive Phase 2a Trial WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN ) today announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG...

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CR(R) (zolpidem tartrate extended-re...

Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder

MOUNTAIN VIEW, Calif., June 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today preliminary results from its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. The study did not meet its two prima...

New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder

First Extensive Report of Bile Acid Aberration in Type 2 Diabetes Patients Warrants Further Study EMERYVILLE, Calif. and PARSIPPANY, N.J., June 9 /PRNewswire-FirstCall/ -- KineMed, Inc., and Daiichi Sankyo, Inc., announced that researchers have discovered a key differenc...

Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder

- Findings Published in the British Journal of Hematology - FREMONT, Calif., April 24 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML ) today reported findings from an Ohio State University (OSU) clinical study that indicated that a surface-enhanced laser desorption/ionization ...

Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder

- Clinical evidence for unique Ranexa(R) mechanism of action - CHICAGO, March 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that ranolazine significantly (p<0.001) shortened the QT interval of patients with a hereditary form of long QT syndrome called...

FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder

INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults. "Relapse, the re-emergenc...

Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder

WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN ) today announced positive results from a Phase 2a clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder. This was a multi-center study in which 84 patients received eithe...

Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder

HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline (NYSE: GSK ) announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone exten...

Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder

Shows Treatment Significantly Effective at Eight Weeks CINCINNATI, Oct. 26 /PRNewswire/ -- In the largest pediatric study of its kind on mood stabilizers, scientists from Cincinnati Children's Hospital Medical Center and two other centers demonstrated that divalproex sodium (Depakote(...

Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter

BOSTON, April 25, 2007 /PRNewswire-USNewswire/ -- At least one-third of the time, the symptoms of bipolar disorder first appear in childhood or adolescence. However, in children, it can be difficult to distinguish bipolar symptoms from those of other disorders, notes the May 2007 issue of the Harv...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed No Significant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Findings from two separate pooled analyses - one examining the effect of desvenlafaxine succinate on anxious symptoms and...

International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinson's Disease

Results presented at the Movement Disorder Society's 11th International Congress in Istanbul, Turkey KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- New information on the use of AZILECT(R) (rasagiline tablets) for the treatment of Parkinson's disease (PD) was reported this week at The M...

IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders

HAYWARD, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - IMPAX Laboratories, Inc. (OTC:IPXL) today announced that two poster presentations, highlighting the company's compound, IPX054, a combined immediate- and extended-release carbidopa/levodopa (CD/LD) product to be marketed as VADOVA(TM), were presented ...

Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatally flawed CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findings presented yesterday at a National Autism Association meeting bolster claims that vaccines may play a role in the development of autism spectrum disorders. David Ay...

Latest NIMH Study on Bipolar Disorder

Statement of Ken Duckworth, M.D., Medical Director National Alliance on Mental Illness (NAMI) ARLINGTON, Va., April 02, 2007 /PRNewswire-USNewswire/ -- Today the Archives of General Psychiatry published a study on the effectiveness of psychosocial treatments for bipolar disorder, "Psychosocial Tre...

Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder

Relationship Between Ability to Function and Treatment of Anxious and Painful Physical Symptoms Studied INDIANAPOLIS, May 21, 2007 /PRNewswire-FirstCall/ -- Data suggest that patients with generalized anxiety disorder (GAD) treated with Cymbalta(R) (duloxetine HCl) experienced improved ability to ...